Close Menu

Barry Hextall

Jun 04, 2015

Premaitha Health has appointed Barry Hextall as Chief Financial Officer, replacing Mark Collingbourne. 

Hextall has more than 15 years of experience in senior financial roles. He has worked previously at JRI Orthopaedics, Immunodiangostic Systems, and Ernst & Young. 

More Like This

Apr 18, 2019

Ori Karev

Ori Karev has joined Precipio as chief strategy officer. Karev was formerly CEO of UnitedHealthcare Global, the international division of United Healthcare. He also previously worked for Ernst & Young. An attorney by training, Karev has more than 30 years of experience in the healthcare, insurance, and mobility industries, Precipio said.

Apr 17, 2019

Carsten Ullrich

Centogene has appointed Carsten Ullrich its director of artificial intelligence. He will direct the firm's use of AI to enhance diagnostic effectiveness and quality, and to discover new insights, accelerate biomarker development, and drive solutions for drug firms. Ullrich was most recently associate head of a research lab and senior researcher at the German Research Center for Artifidal Intelligence. 

Apr 16, 2019

Marijn Dekkers

Marijn Dekkers has been named chairman of the board of synthetic biology firm Ginkgo Bioworks. He also will serve as a strategic advisor of the Boston-based company. Dekkers most recently served as CEO of Bayer AG, and prior to that was CEO of Thermo Fisher Scientific. He also currently serves as chairman of Unilever and is founder and chairman of Novalis LifeSciences, a boutique investment and advisory firm.

Apr 15, 2019

James Corbett

PerkinElmer said recently that Executive Vice President and President of Discovery & Analytical Solution James Corbett is leaving the company on April 30. His departure follows a "conversation" between PerkinElmer and Corbett, the company said in a document filed with the US Securities and Exchange Commission. 

Apr 05, 2019

Andrew Brooks

Circuit Clinical, an integrated research organization that facilitates clinical trials and biospecimen collection, has added Andrew Brooks to its board of directors. Brooks is currently chief operating officer of RUCDR Infinite Biologics (RUCDR) at Rutgers University, the world's largest academic biorepository managing biological resources for clients such as the National Institutes of Health, as well as leading academic researchers and major pharmaceutical and biotechnology companies. He is a professor of genetics at Rutgers University and a member of the Human Genetics Institute of New Jersey.

Apr 05, 2019

Joseph Driscoll

Akoya Biosciences, which markets tools for high-parameter tissue analysis and biomarker discovery, has appointed Joseph Driscoll as CFO. Driscoll most recently served as CFO at Quanterix. He has also served as CFO at several other public and private companies, including Verscend, PC Connection, Summer Infant, ACT Electronics, and Safety 1[st].

Apr 03, 2019

Ilan Daskal

Bio-Rad Laboratories has appointed Ilan Daskal as executive vice president and CFO. Daskal previously served as CFO of Lumileds, a lighting manufacturer formed in 1999 as a joint venture between Philips Lighting and Agilent Technologies. He will replace Christine Tsingos, who is retiring.

Apr 03, 2019

James Marsden

LexaGene has appointed James Marsden to its scientific advisory board. Marsden previously served as the executive director of food safety at Chipotle from 2016 to 2019. According to LexaGene, Marsden has also worked for several food companies and techology providers. Prior to Chipotle, he acted as VP for scientific affairs and President at the American Meat Institute. In addition, Marsden also held the role of a professor at Kansas State University. 

Apr 02, 2019

Aaron Tachibana

Personalis has appointed Aaron Tachibana as CFO. Tachibana previously served as CFO of Lumentum Holdings. Prior to joining Lumentum, Tachibana was VP of finance at JDS Uniphase. He holds a BS in business administration and finance from San Jose State University. 

Apr 02, 2019

Flemming Ornskov

Flemming Ornskov was appointed to Centogene's supervisory board and elected its non-executive chairman, effective April 1. He most recently was CEO of Shire. Prior to that, he held senior positions at several pharmaceutical firms, such as Bayer, Novartis, and Merck & Co. As a non-executive chairman, Ornskov will oversee Centogene's strategy development, US expansion, and strategic M&A. 

Apr 01, 2019

Marc Williams, Karen Gripp, Dietrich Matern, Michael Murray, Cynthia Powell, Heidi Rehm

Marc Williams has been announced as president-elect of the American College of Medical Genetics and Genomics. He is the director of the Geisinger Genomic Medicine Institute. Prior to joining Geisinger in 2012, he was the director of Intermountain Healthcare's Clinical Genetics Institute. Williams is a board-certified pediatrician and holds an MD as well as an undergraduate degree in chemistry from the University of Wisconsin-Madison.

Williams and five others have also been elected to the ACMG's board of directors for a six-year term that starts this month. The other new directors are Karen Gripp, chief of the Division of Medical Genetics at the Nemours/Alfred I. duPont Hospital for Children and medical director of its molecular diagnostics laboratory; Dietrich Matern, chair of the Division of Laboratory Genetics and Genomics in the Department of Laboratory Medicine and Pathology at the Mayo Clinic; Michael Murray, director of clinical operations in the Center for Genomic Health at Yale University School of Medicine; Cynthia Powell, director of the medical residency program and medical director of the UNC Hospitals Cytogenetics Laboratory; and Heidi Rehm, chief genomics officer at Massachusetts General Hospital and medical director of the Broad Institute's clinical laboratory.

Mar 29, 2019

William Moss, Brandi Davis-Dusenbery

Seven Bridges has named promoted William Moss to CEO from his previous role as chief operations officer and president of commercial operations. He replaces Brandi Davis-Dusenbery, who has moved into the newly created position of chief scientific officer for the company. Davis-Dusenbery had been CEO since March 2017.

Mar 29, 2019

Amol Chaubal

Quanterix said this week that it has appointed Amol Chaubal as CFO, effective April 12, 2019. He replaces Joseph Driscoll, who is stepping down as CFO. Chaubal joins Quanterix from medical device firm Smith & Nephew, where he currently serves as CFO of global operations. Prior to Smith & Nephew, he served as corporate VP and head of finance for Parexel's CRS business, and has also held various roles at Novartis, including CFO North America – Vaccines & Diagnostics.

Mar 28, 2019

Bob Petrou

NantHealth has removed the "interim" tag from CFO Bob Petrou, company CEO Patrick Soon-Shiong disclosed today in a conference call with reporters and financial analysts. Petrou joined NantHealth in September following the resignation of former CFO Paul Holt.

Mar 27, 2019

Rob Treanor, Andrew Campbell

Sphere Fluidics has appointed Rob Treanor and Andrew Campbell as director of operations and director of finance, respectively. Treanor has previously held positions running large logistics and supply teams within the biotechnology sector. Campbell previously held senior positions at various global life sciences companies, including Charles Rivers and PerkinElmer Life Sciences.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.